While TNF inhibitors remain pivotal for biologic-naive patients, IL-23 inhibitors, particularly risankizumab, are emerging as a preferred option for patients with refractory or biologic-exposed CD, offering efficacy across a broader spectrum of disease severity. Here, TNF is linked to Cowden disease.